A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

NCT05908786 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: Tiragolumab
DRUG: Tobemstomig

Sponsor

Hoffmann-La Roche